Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 15, 133-138, February 1, 1955]
© 1955 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dietrich, L. S.
Right arrow Articles by Shapiro, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dietrich, L. S.
Right arrow Articles by Shapiro, D. M.

Testosterone Augmentation of Deoxypyridoxine Antagonism of Various Vitamin B6-containing Enzyme Systems in Tumor and Host Tissue*

L. S. Dietrich and D. M. Shapiro{dagger}

( Departments of Biochemistry and Surgery, College of Physicians and Surgeons, Columbia University, New York, N.Y.)

1. Testosterone, administered in vivo, was observed to have no effect on glutamic-aspartic transaminase, glutamic-alanine transaminase, DOPA decarboxylase, and cysteine desulfhydrase activity of the tumor (755) and normal mouse tissues studied. Similar results were obtained for glutamic-aspartic and glutamic-alanine transaminase activity in liver and skeletal muscle utilizing slice technics.
2. The in vivo administration of testosterone and deoxypyridoxine in combination increased the sensitivity of glutamic-aspartic transaminase, glutamic-alanine transaminase, and DOPA decarboxylase to antagonism by deoxypyridoxine, the point of maximal inhibition being reached at an earlier time than when the antagonist was administered alone. Deoxypyridoxine, alone or in combination with testosterone, had no effect on cysteine desulfhydrase activity.
3. The administration of pyridoxine 1/2 hour prior to the administration of deoxypyridoxine was observed to protect glutamic-aspartic transaminase from deoxypyridoxine inhibition regardless of whether the antagonist was given alone or in combination with the testosterone.

* This work was supported by a grant-in-aid from the Damon Runyon Memorial Fund, the Mary Madison McGuire Memorial Fund and an anonymous cancer gift. A preliminary report appeared in Fed. Proc., 12:412, 1953.

{dagger} Fellow of the Dazian Foundation for Medical Research, Inc.

Received 11/ 3/54.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1955 by the American Association for Cancer Research.